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Multidrug resistance (MDR) counteracts the efficieny of sorafenib, an important first-line therapy for
hepatocellular carcinoma (HCC). Sirtuins (SIRTs) 1 and 2 are associated with tumor progression and MDR. We 
treated 2D and 3D cultures (which mimic the features of in vivo tumors) from HCC cells with sorafenib alone or 
in the presence of SIRTs 1 and 2 inhibitors (cambinol or EX-527; combined treatments). Cultures subjected to 
combined treatments showed a greater fall in cellular viability, proliferation (PCNA, cyclin D1 and Ki-67 
expression and cell cycle analysis), migration and invasion when compared with cultures treated only with
sorafenib. Similarly, combined treatments produced more apoptosis (annexin V/PI, caspase-3/7 activity) than 
sorafenib alone. Since cell cycle dysregulation and poptotic blockage are reported mechanisms of MDR, the 
modulation found in PCNA, cyclin D1, Ki-67 and caspe-3/7 proteins by cambinol and EX-527 are probably 
playing a role in enhancing the sensitivity of HCC cell lines to sorafenib. EX-527 reduced MRP3 and BCRP 
expression in sorafenib-treated HCC cells. Since ABC transporters contribute to MDR, MRP3 and BCRP could 
be also influencing in the response of HCC cells to orafenib. Overall, 2D and 3D cultures behave similarly 
except that 3D cultures were less sensitive to treatm nts, reinforcing the clinical relevance of the current study. 
Findings presented in this manuscript support a potential application for SIRTs 1 and 2 inhibitors since we 
demonstrated that these compounds enhance the inhibitory effect of sorafenib upon treatment of hepatocellular 
carcinoma cells lines. 
 

























1. Introduction  
Sorafenib is one of the first-line treatments for hepatocellular carcinoma (HCC); however, it only prolongs 
median overall survival by nearly 3 months (Faivre et al., 2020). One of the main reasons underlying this feature 
is the multidrug resistance (MDR) (Chen et al., 2015). MDR is a major cause of HCC recurrence and metastasis 
(Ceballos et al., 2019), with different resistance m chanisms against the same drug acting in the sametumor cell 
(Kartal-Yandim et al., 2016). Additionally, many patients require dose reduction to minimize adverse effects 
exerted by sorafenib (Gadaleta-Caldarola et al., 2015).  
Sirtuins (SIRTs) are class III histone deacetylase enzymes. Among SIRTs members, SIRTs 1 and 2 are reported 
to play crucial roles in cellular proliferation, migration and invasion and in the blockage of apoptosis and are 
related to the promotion of tumor initiation, progression and metastasis in HCC (Chen et al., 2013; Li et al., 
2016; Wu et al., 2015; Xie et al., 2011). These studies also showed a positive correlation between SIRTs 1 and 2 
expression and poor prognosis in patients with this malignancy. SIRTs 1 and 2 are upregulated in HCC cell lines 
and in a subset of human HCC tissues when compared to normal hepatocytes and nontumoral tissues, 
respectively (Chen et al., 2013; Li et al., 2016; Portmann et al., 2013; Xie et al., 2011). Deacetylation of key cell 
cycle molecules and apoptosis regulatory proteins by SIRTs 1 and 2, including p53 and FoxO, abolishes t  
capability of these tumor suppressors to induce cell growth arrest and apoptosis (Wang et al., 2019). In this 
regard, dysregulation of cell cycle checkpoints andblockage of apoptotic signals are mechanisms involved in 
MDR (Kartal-Yandim et al., 2016). At the same time, it was demonstrated that SIRT1 overexpression in HCC 
cells induces the upregulation of P-glycoprotein (P-gp), an ATP binding cassette (ABC) efflux transporter (Jin et 
al., 2015). ABC transporters are overexpressed in HCC cells and also contribute to MDR (Ceballos et al., 2019). 
Indeed, SIRT1 overexpression was associated with resistance to sorafenib and other chemotherapeutic drugs in 
HCC cell lines (Chen et al., 2012; J. Chen et al., 2011; Liang et al., 2008).  
Based on the functional role of SIRTs 1 and 2, their inhibition might be of great value in the development of new 
therapeutic targets in HCC. We reported that two SIRTs 1 and 2 inhibitors, cambinol and EX-527, decreased 
cellular viability, the number of colonies and cellular migration and increased apoptosis in 2D cultures of HCC 
cell lines (Ceballos et al., 2018). These compounds were also able to decrease the viability and growth of 3D cell 
cultures. In addition, we demonstrated that SIRT1 and SIRT2 modulation by cambinol and EX-527, as well as 
by silencing technology, affected the expression of P-gp and multidrug resistance-associated protein 3 (MRP3), 










The aim of the present study was to analyze whether cambinol and EX-527 have the potential to enhance the 
response of HCC cells to sorafenib in 2D and 3D culture models. We focused particularly in assessing the impact 
of treatments on cellular viability, proliferation, migration, invasion and apoptosis. We also explored th  effect 
of treatments on expression of ABC transporters in 2D cell cultures. 
 
2. Materials and methods 
2.1. Chemicals and antibodies 
Sorafenib (10009644) was from Cayman Chemical (Ann rbor, MI, USA). Cambinol (C0494) and EX-527 
(E7034) drugs and anti-β-Actin (A2228) and anti-MRP3 (M0318) antibodies were obtained from Sigma-Aldrich 
Corp. (St. Louis, MO, USA). Anti-PCNA (sc-56), anti-P-glycoprotein (sc-55510) and anti-BCRP (sc-58222) 
antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-Cyclin D1 antibody 
(ab134175) was obtained from Abcam (Cambridge, MA, USA). Anti-Ki67 antibody (PA5-19462) was obtained 
from Thermo Fisher Scientific (Rockford, IL, USA). Anti-MRP2 antibody (ALX-801-016) was from Enzo Life 
Sciences, Inc. (Farmingdale, NY, USA). All other chemicals were of the highest grade commercially avail ble.  
 
2.2. Studies in 2D cell cultures 
2.2.1. Cell lines and treatments  
The human HCC cell lines HepG2 and Huh7 were obtained from ATCC (Manassas, VA, USA) and JCRB Cell 
Bank (Tokyo, Japan), respectively. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 µg/ml streptomycin at 37°C in 
a humidified atmosphere of 95% O2 and 5% CO2. In order to inhibit SIRTs 1 and 2 activities, two inhibitors 
were used in combination with sorafenib, cambinol and EX-527; since they have shown promising results in 
vitro and in vivo as antitumor agents, alone or in combination with other drugs (Asaka et al., 2015; Bhalla and 
Gordon, 2016; Chen et al., 2017; Heltweg et al., 2006; Marshall et al., 2011; Portmann et al., 2013). Cambinol 
and EX-527 target both SIRT1 and SIRT2. However, while cambinol inhibits SIRT1 and SIRT2 with similar 
IC50s (IC50 SIRT1 = 56 μM; IC50 SIRT2 = 59 μM), EX-527 is much more selective for SIRT1 than for SIRT2 
(IC50 SIRT1 = 0.1-1 μM; IC50 SIRT2 = 20-33 μM) (Lugrin et al., 2013). Cambinol binds to the nicot namide 
binding pocket of SIRTs 1 and 2 and exhibits competitiv  inhibition toward the acetyl-lysine peptide sub trate 
and noncompetitive toward NAD+ (Heltweg et al., 2006). EX-527 binding to the nicot namide binding pocket of 










with the substrate and uncompetitive with NAD+. EX-527 forms a complex with a coproduct of the reaction, 
stabilizing a closed enzyme conformation and preventing product release (Gertz et al., 2013; Napper et al., 
2005).  
After 24 h of attachment, cells were treated for 72 h with different doses of sorafenib to obtain dose-response 
curves. Alternative, in most experiments, after attachment cells were treated for 72 h with 50 μM cambinol 
(Camb 50); 40 μM EX-527 (EX 40); 2 μM or 1 μM sorafenib (Sfb 2 or Sfb 1) for HepG2 and Huh7 cells, 
respectively; and sorafenib combined with cambinol or EX-527 (combined treatments: Sfb + Camb 50 or Sfb + 
EX 40). All drugs were dissolved in dimethylsulfoxide (DMSO). Control (untreated) cells were incubated only 
with DMSO, with a final concentration in the culture medium always below 0.5%. 
 
2.2.2. MTT assay 
Cells were seeded in 96-well plates at a density of 10,000 cells/well for HepG2 and 4,000 cells/well for Huh7. 
After attachment, cells were treated with different doses of sorafenib or with the treatments indicated in section 
2.2.1. After treatment, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma-Aldrich 
Corp.) was added into the culture medium to assess its metabolization, as previously described (Ceballos et al., 
2018). Absorbance of the metabolite produced from viable cells was detected at 540 nm (reference filter 650 nm) 
in a DTX 880 multimode detector (Beckman Coulter Inc., Fullerton, CA, USA). Results were expressed as 
percentage of absorbance in control cells. The half-m ximal inhibitory concentration resulting in 50% cell-
growth inhibition (IC50) was determined using CompuSyn software (ComboSyn, Paramus, NJ).  
 
2.2.3. Clonogenic survival assay 
Cells were seeded in 6-well plates at a density of 8,000 cells/well for HepG2 and 500 cells/well for Huh7, 
cultured overnight and treated for 72 h. After treatment, cells were cultured in fresh medium without drugs for 7 
days. Media were replaced every 2-3 days. Finally, cell colonies were washed twice with PBS, fixed with 
methanol for 10 min and stained with toluidine blue (1% (W/V) in 1% (W/V) sodium borate) for 5 min. The 
plates were rinsed with water, air-dried, photographed and evaluated for colony estimation. Colonies wre 
counted and relative colony formation was determined by the ratio of the average number of colonies in treated 
cells to the average number of colonies in control cells.  
 









Cells were seeded in 6-well plates at a density of 500,000 cells/well for HepG2 and 250,000 cells/well for Huh7. 
After treatment, cells were washed, scrapped, colleted and resuspended in homogenization buffer (250 mM 
sucrose, 20 mM Tris-HCl, 5 mM EDTA; pH 7.4) containing protease inhibitors to obtain total cell homogenat s. 
The protein concentration was determined by Sedmak and Grossberg method (Sedmak and Grossberg, 1977), 
using bovine serum albumin (BSA) as a standard. 
Equal amounts of proteins (20 µg per lane) were resolv d by 8% or 12% SDS-PAGE and electroblotted onto 
polyvinyl difluoride (PVDF) membranes (PerkinElmer Life Sciences Inc., Boston, MA, USA). Immunoblots 
were blocked with PBS-10% nonfat milk, washed and incubated overnight at 4°C with primary antibodies. 
Finally, membranes were incubated with peroxidase-conjugated secondary antibodies and bands were detected 
by enhanced chemiluminescence (ECLTM) detection system (Thermo Fisher Scientific). The immunoreactive 
bands were quantified by densitometry using the Gel-Pro Analyzer software (Media Cybernetics, Silver Sp ing, 
MD, USA). Equal loading and transference of protein was checked by detection of β-actin and by Ponceau S 
staining (latter data not shown) of the membranes. 
 
2.2.5. Cell cycle analysis  
Cells were seeded in 6-well plates at a density of 500,000 cells/well for HepG2 and 250,000 cells/well for Huh7 
and treated the next day for 72 h. Then, cell distribu ion in the cell cycle was analyzed by determining the 
cellular DNA content by flow cytometry, as we previously described (Ferretti et al., 2019). Briefly, 1 × 06 cells 
were fixed with cold 70% ethanol, washed with PBS and stained with 50 μg/ml propidium iodide (Sigma-
Aldrich Corp.) in a buffer solution (0.1% sodium citrate, 0.02 mg/ml RNAse, and 0.3% NP-40). Results were 
analyzed using WinMDi and Cylchred software. 
 
2.2.6. Annexin V/propidium iodide assay  
Cells were seeded in 6-well plates at a density of 500,000 cells/well for HepG2 and 250,000 cells/well for Huh7 
and treated the next day for 72 h. After detachment of cells, apoptotic cell death was assessed by Annexi  V-
FITC and propidium iodide staining (FITC Annexin V Apoptosis Detection Kit II;BD Biosciences, San Jose, 
CA, USA) coupled to flow cytometric analysis (BD FACSAria™ II cell sorter flow cytometer, BD Biosciences), 
as previously described (Ceballos et al., 2018).  
 










The activity of caspase-3/7 was determined with the CellEvent™ Caspase-3/7 Green ReadyProbes™ Reagent 
(Thermo Fisher Scientific). This reagent is a novel non-toxic fluorogenic substrate for activated caspases 3 and 7 
and consists of a four amino acid peptide (Asp-Glu-Val-Asp: DEVD) conjugated to a nucleic acid binding dye. 
DEVD is the consensus sequence cleaved by caspases 3 nd 7 in their substrates. This cell-permeant substrate is 
intrinsically non-fluorescent, because the DEVD peptide inhibits the ability of the dye to bind to DNA. fter 
activation of caspase-3 or caspase-7 in apoptotic cells, the DEVD peptide is cleaved, enabling the dye to bind to 
DNA and produce a bright, fluorogenic response with absorption/emission maxima of ~502/530 nm.  
Cells were seeded in 96-well plates at a density of 12,000 cells/well for HepG2 and 4,000 cells/well for Huh7. 
After treatment, 10 µl of reagent was added per well and cells were incubated for 30 min at 37°C in a humidified 
atmosphere of 95% O2 and 5% CO2. Cells were observed using an inverted fluorescence mi roscope (Zeiss 
Axiovert 25; Zeiss, Oberkochen, Germany) connected to a digital camera (Nikon Coolpix 990; Nikon, Toky, 
Japan).  
 
2.2.8. Wound healing assay  
Cells seeded at 3×106/well for HepG2 and 1×106/well for Huh7 were cultured in 6-well plates. After 24 h, cells 
were wounded by dragging a 200 μl pipette tip through the confluent monolayer, washed with PBS and treated 
for 24 h to allow migration. Images of wounds in the same field were captured when the scrape wound was 
introduced (0 h) and after 24 h of wounding (18 fields/well) using an inverted microscope (Zeiss Axiovert 25) 
connected to a digital camera (Nikon Coolpix 990). The area and height of the wound were determined using 
ImageJ software (NIH) and the healing width was calcul ted as the area to height ratio. The migrated distance 
(μm) was then calculated with the formula = wound width at 0 h - wound width at 24 h, and expressed as 
percentage relative to control cells.  
 
2.2.9. Transwell cell invasion assay  
Invasion assay was performed using transwell chambers with 8 μm pore size polyester membrane filters (Biofil, 
Beijing, China) precoated with ECM gel (Sigma-Aldrich Corp.). Huh7 cells in DMEM containing 1% FBS were 
harvested and reseeded in the upper chambers at a density of 50,000 cells per well, and the lower chambers were 
filled with complete DMEM medium containing 10% FBS. Treatments were added to upper and lower 
chambers. After 48 h, ECM gel and remaining cells (non-invasive cells) on the top surface of the membrane in 










bottom surface of the membrane were fixed and stained i  the same way as for colonies. For quantificaton, cells 
in 15 randomly selected microscopic fields were photographed and counted using an inverted microscope. Cells 
that invaded the lower chambers were expressed as percentage relative to control cells. 
 
2.3. Studies in 3D cell cultures (spheroids) 
Three-dimensional cell culture models such as spheroids closely mimic the main features of human solid tumors 
and manifest an elevated MDR compared to 2D cell cultures thus representing valuable in vitro models for the 
preclinical evaluation of anticancer drug treatments (Mehta et al., 2012; Vinci et al., 2012).  
 
2.3.1. Generation of spheroids and treatments  
Spheroids from HCC cells were obtained by liquid overlay technique in 96-well plates as previously described 
(Ceballos et al., 2018). Briefly, wells were coated with a mixture of 3% agarose in water (W/V): DMEM (1:1) 
and 2 h later HepG2 and Huh7 cells were seeded at a ensity of 1,500 cells/well. Culture conditions were the 
same as for 2D cell cultures. Spheroids were formed after an initiation interval of 4 days (0 h) and then treated 
until day 7 (72 h) with different concentrations of s rafenib (APH and spheroid growth delay assays) or with 50 
μM cambinol (Camb 50); 80 μM or 40 μM EX-527 (EX 80 or EX 40) for HepG2 and Huh7 cells, respectively; 4 
μM or 2 μM sorafenib (Sfb 4 or Sfb 2) for HepG2 and Huh7 cells, respectively; and sorafenib combined with 
cambinol or EX-527 (combined treatments: Sfb + Camb or Sfb + EX). All drugs were dissolved in DMSO. 
Control (untreated) spheroids were incubated only with DMSO, with a final concentration in the culture medium 
always below 0.5%. Spheroids were treated by replacing 50% of the supernatant by fresh medium supplemented 
with drugs prepared at twice of the desired doses.  
Techniques to avoid spheroids disaggregation and thus to study the behavior of whole spheroids were chosen. In 
this way, we were able to visualize drug response i different regions of spheroids.  
 
2.3.2. Spheroid viability and growth: acid phosphatase and spheroid growth delay assays  
Spheroids were treated for 72 h with different doses of sorafenib or with the treatments indicated in section 2.3.1. 
and then the acid phosphatase (APH) assay was perform d for viability assessment, according to the protoc l of 
Friedrich et al. (Friedrich et al., 2007). The substrate p-nitrophenyl phosphate was kindly provided by Wiener 










detector. Results were expressed as percentage of abs rb nce in control cells. The IC50 was determined using 
CompuSyn software. 
For assessing the volume of 3D cell cultures, spheroids images were captured before (day 4; 0 h) and after (day 
7; 72 h) treatments using an inverted microscope (Zeiss Axiovert 25) connected to a digital camera (Nikon 
Coolpix 990) and diameters were determined using ImageJ software. Spheroids diameters at the onset of 
treatment were close to 400 - 500 µm, as recommended (Friedrich et al., 2009; Vinci et al., 2012). In this regard, 
spheroids with diameters larger than 400 µm follow a concentrically layered structure consisting of an 
apoptotic/necrotic core surrounded by a viable layer of quiescent cells and an outer ring of proliferating cells 
(Hirschhaeuser et al., 2010; Mehta et al., 2012). This cellular heterogeneity is similar to that of avascular 
microregions of tumors (Hirschhaeuser et al., 2010; Mehta et al., 2012) and, in the same way, the concentration 
of drugs, oxygen and nutrients decreases in the distant inner cells of spheroids contributing to MDR (Mehta et 
al., 2012). Spheroids volumes were calculated before and after treatments using the equation: V = (4/3)πR3; R = 
(D1 + D2)/4, where D1 and D2 are the maximal diameters of spheroids measured in the rectangular direction. 
Results were expressed as the percentage of volume at 72 h vs. 0 h (Ceballos et al., 2018).  
 
2.3.3. Immunofluorescent analysis of spheroid sections 
To obtain frozen sections, spheroids were harvested af r treatments and transferred to Eppendorf tubes (~20 
spheroids/tube), rinsed twice with PBS and fixed in 4% paraformaldehyde for 1 h. After fixation, spheroids were 
rinsed twice with PBS, transferred to cryomolds andembedded in Cryoplast compound (Biopack, Buenos Aires, 
Argentina) for cryostat sectioning (Microm HM 500; Zeiss). Sections of 8 μm were obtained, mounted onto 
slides and stored at -70ºC until used. For immunostaining, sections were permeabilized and blocked with 3% 
BSA and 0.3% Triton X-100 in PBS for 20 min and then incubated overnight at 4°C with primary antibodies. 
After washes in PBS, sections were incubated with appropriate Cy2- or Cy3-conjugated secondary antibodies 
(Jackson ImmunoResearch Laboratory, Inc., West Grove, PA, USA) for 1 h, washed, incubated for nuclei 
staining with 4′,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific) and mounted with ProLong 
(Thermo Fisher Scientific). Fluorescence was detectd by using confocal microscopy (Nikon C1SiR with 
inverted microscope Nikon TE200E and Zeiss LSM880). Images were obtained with the confocal software and 
then processed using ImageJ software. To ensure comparable staining and image capture performance for control 
and treated cells, all groups were processed in parallel. For quantification, the number of positive cells for Ki-67, 










using the ITCN (Image-based Tool for Counting Nuclei) plugin of the ImageJ software. The total number of Ki-
67-, PCNA- and cyclin D1-positive stained cells pers ction of spheroid and the fraction of Ki-67-, PCNA- and 
cyclin D1-positive cells per total number of cells per section of spheroid (proliferation marker positive 
cells/DAPI-positive cells) was determined in at least 8 sections of spheroids from two independent experiments 
and data was expressed as percentage relative to thc ntrol group.    
 
2.3.4. Caspase-3/7 activation assay  
As for 2D cultures, the activity of caspase-3/7 was determined with the CellEvent™ Caspase-3/7 Green 
ReadyProbes™ Reagent. This reagent was validated in fresh whole spheroids and showed no toxicity for 
cultures (Mittler et al., 2017). After treating spheroids the same protocol used for 2D cultures was applied 
(section 2.2.7.), except that 20 µl of reagent was added per well and spheroids were incubated for 1 h prior to 
microscopic observation. Fluorescence intensity was measured using ImageJ software and data was expressed a  
percentage relative to control cells. 
 
2.3.5. Spheroid migration assay 
Migration was assessed in whole spheroids based on the protocol by Xu et al. (Xu et al., 2012), with slight 
modifications. Spheroids from the Huh7 cell line were obtained and photographed before treatment (day 4; 0 h) 
using an inverted microscope connected to a digital camera. Spheroids were then transferred to 96-well plates 
without base-coated agarose to allow their adhesion to wells. Under these conditions, spheroids are abl  to 
disassemble and release cells that have the ability to migrate. Once transferred, spheroids were treated in serum 
free medium to attenuate cellular proliferation and the process of migration was followed obtaining images at 24, 
48 and 72 h, using an inverted microscope. Diameters w e determined using ImageJ software at 0, 48 and 72 h 
and areas were calculated using the equation: A = 4πR2; R = (D1 + D2)/4, where D1 and D2 are the maximal 
diameters of spheroids measured in the rectangular direction. The migration capability was then estimaed by 
relativizing the area covered by the spheroid together with the cells that have migrated from it at 48 or 72 h to 
the initial area of the spheroid at 0 h and expressing results as percentage of the control group (Vinci et al., 
2012). 
 










Results were expressed as mean ± S.E.M. Significance in differences was tested by one-way ANOVA followed 
by Tukey test. Differences were considered significant when the P value was < 0.05.  
 
3. Results 
3.1. The presence of cambinol or EX-527 increments the cytotoxic effect of sorafenib 
Two-dimensional cultures were treated with different doses of sorafenib for 72 h. As expected, sorafenib reduced 
cellular viability in a dose-dependent manner compared with control cells in HepG2 and Huh7 cell lines (Fig. 1 
A). The IC50 (µM) for sorafenib was 4.32 ± 0.54 in HepG2 cells and 2.88 ± 0.38 in Huh7 cells. Based on this 
result, we choose one dose of sorafenib for each HCC cell line for further studies; 2 µM (Sfb 2) for HepG2 and 1 
µM (Sfb 1) for Huh7 cells. These doses generated a small but significant reduction of cell viability (below the 
IC50 values) that was of similar extent in both cell lines. 
Next, we analyzed if cambinol and EX-527 were capable of modifying the cytotoxic effect of sorafenib in 2D 
cultures. Doses for cambinol and EX-527 were chosen based on the results from our previous study and were the 
same for both cell lines; 50 µM for cambinol (Camb 50) and 40 µM for EX-527 (EX 40) (Ceballos et al., 2018). 
The selection was also based on the fact that cambinol and EX-527 were able to inhibit SIRT1 and SIRT2 at 
these doses (Ceballos et al., 2018; Lugrin et al., 2013). As seen in Fig. 1 B, the addition of cambinol or EX-527 
as a combined treatment (Sfb + Camb 50 or Sfb + EX 40) significantly raised sorafenib cytotoxicity in 2D 
cultures of both HCC cell lines. The clonogenic assay confirmed the toxicity of the different treatments and was 
in accordance with MTT results as the lowest percentages of colonies were obtained with the combined 
treatments (Fig. 1 C).  
In the case of 3D cell cultures, data show a dose-dependent reduction of spheroid viability after sorafenib 
treatment when compared with untreated spheroids from both cell lines (Fig. 2 A). The IC50 values (µM) for 
sorafenib were 11.70 ± 0.60 in HepG2 and 8.17 ± 1.01 in Huh7 spheroids. Importantly, these values were 
significantly higher than those from the respective 2D cultures (Fig. 1 A), indicating a lower sensitivity of 
spheroids to sorafenib treatment (P < 0.05 vs. 2D). 
Following the same strategy used in 2D cultures, we choose one dose of sorafenib for each HCC cell lin for 
further studies; 4 µM (Sfb 4) for HepG2 and 2 µM (Sfb 2) for Huh7 spheroids. As shown in Fig. 1, these doses 
generated a small but significant reduction of cellviability that was comparable between cell lines and the doses 
were higher than those chosen for 2D cultures due to the increased resistance of spheroids to sorafenib. Although 










both cell lines, we had to increase the dose of EX-527 in 3D cultures from HepG2 cells (80 µM; EX 80) due to 
the high resistance of HepG2 spheroids to this drug(Ceballos et al., 2018). The addition of cambinol or EX-527 
as a combined treatment significantly increased sorafenib cytotoxicity in spheroids from both HepG2 and Huh7 
cells (Fig. 2 B).  
 
3.2. SIRTs inhibitors lead to a diminution of cellular proliferation during sorafenib treatment  
To analyze if the addition of SIRTs inhibitors during sorafenib treatment affects the proliferation of 2D cultures, 
we quantified the levels of proliferating cell nuclear antigen (PCNA) and cyclin D1 proteins by western blot. 
Whereas Cambinol and EX-527 were able to reduce PCNA and cyclin D1 protein levels, sorafenib failed to 
diminish the levels of these proteins (Fig. 3 A, B). However, when sorafenib was combined with the inhibitors a 
significant reduction was achieved in both HCC celllines (Fig. 3 A, B). Next, we studied the effect of reatments 
on cell cycle progression in 2D cultures. Although changes were small, we observed that the population of cells 
in G0/G1 was increased and that of S was reduced by treatments with the greatest variations obtained with the 
combined treatments (Fig. 3 C). No significant effects were registered in the population of cells in G2/M with 
treatments (data not shown).  
As a measure of proliferation in 3D cultures, we calcul ted the volume of the spheroids before and after 
treatments (Vinci et al., 2012). Sorafenib alone induced a concentration-dependent growth inhibition in HepG2 
and Huh7 spheroids (Fig. 4 A). As shown in Fig. 4 (B, C), cambinol and EX-527 exacerbated the effect of 
sorafenib on volume reduction of HepG2 and Huh7 spheroids.  
To further explore the antiproliferative capacity of treatments in 3D cultures we evaluated the expression of Ki-
67, PCNA and cyclin D1 proteins by immunofluoresce in frozen sections of spheroids. As shown in Fig. 5 (A, 
B), Ki-67, PCNA and cyclin D1 staining was localized in the peripheral layers of sections of spheroids. 
Compared to control spheroids, treated spheroids from both cell lines generally exhibited a reduction in the 
thickness of the peripheral ring corresponding to cells that were positive for the proliferation markers. In HepG2, 
combined treatments reduced proliferation in spheroid cultures compared to sorafenib treatment as quantified by 
Ki-67, PCNA and cyclin D1 staining (Fig. 5 C-E). The total number of proliferation marker-positive cells per 
spheroid was lower in HepG2 spheroids subjected to combined treatments. Nevertheless, as a consequence of the 
lower number of total cells in treated spheroids, in some cases, the fraction of positive cells was not significantly 
diminished. Only the presence of cambinol in sorafenib-treated spheroids diminished the number of Ki-67- and 









combined treatment with EX-527 and with both combined treatments for cyclin D1 staining, only a non-
significant tendency to reduction of the number of p sitive cells was found in Huh7 regarding to sorafenib-
treated spheroids (Fig. 5 C-E).   
 
3.3. Cambinol and EX-527 raise the apoptotic effect of sorafenib  
Cytometric annexin V-PI assay at 72 h demonstrated that both SIRTs 1 and 2 inhibitors incremented the 
apoptosis observed after sorafenib treatment in 2D cultures from HepG2 and Huh7 cells (Fig. 6 A). Neverth less, 
whereas the combined treatment with Camb 50 incremented early (Annexin V+/PI-) and late (Annexin V+/PI+) 
apoptosis when compared to sorafenib alone, only ear apoptosis was increased with the addition of EX 40 in 
the combined treatment. The same behavior was observed when treating HCC cells only with SIRTs inhibitors; 
i.e., Camb 50 incremented early and late apoptosis while EX 40 raised only early apoptosis, compared with
untreated cells (Fig. 6 A). No changes were found with treatments in primary necrotic death as assessed by 
determination of the Annexin V-/PI+ ratio (data not shown). 
We evaluated caspase-3/7 activity as an alternative method to corroborate the induction of apoptosis in the 
presence of treatments in 2D cultures. As seen in Fig. 6 B, cambinol, EX-527 and sorafenib treatments lead to an 
increment of caspase-3/7 staining intensity and the number of caspase-3/7 positive (apoptotic) cells when 
compared with control cells. In concordance with the annexin V-PI assay, combined treatments produce the 
largest increments in caspase-3/7 activity (Fig. 6 B). Also, according to the cytotoxic effect of treatments, a 
reduction of cell density was observed in cells treated with cambinol, EX-527 and sorafenib that became more 
noticeable after the combined treatments (Fig. 6 B). 
In 3D cultures, we also used the CellEvent™ Caspase-3/7 Green ReadyProbes™ Reagent to evaluate 
apoptosis. As shown in Fig. 7, control spheroids showed a CellEvent-positive central region. More interesting, 
cambinol, EX-527 and sorafenib treatments resulted in an increase of caspase-3/7 staining intensity in spheroids 
core regions, with the largest caspase-3/7 activation observed upon the combined treatments (Fig. 7). 
 
3.4. The addition of SIRTs inhibitors during sorafenib treatment decreases cellular migration and 
invasiveness  
To reduce potential proliferation or apoptosis effects we performed wound healing assays in 2D cultures within a 
short time period (24 h), before the doubling time of HepG2 and Huh7 cells (Sun et al., 2011). Additionally, we 
performed MTT assays to check the effect of treatmen s on cytotoxicity at 24 h. As seen in Fig. 8 A, B, despite 










reduce the migration in 2D cultures. Since cell viabil ty was always > 90% as detected in MTT assays (data not 
shown), we can infer that inhibition of migration by combined treatments is not due to cytotoxic effects.  
In view of the alteration of cell migration in 2D cultures, we evaluated if invasiveness may be also affected. 
Experiments using Huh7 cells showed that cambinol, EX-527 and sorafenib treatments led to a decrease in 
cellular invasion and that the addition of SIRTs 1 and 2 inhibitors to sorafenib treated-cells exacerbated the 
effect of non-combined treatments (Fig. 8 C).  
Then, we analyzed migration in 3D cultures using whole spheroids from Huh7 cells. Although no cellular 
migration was observed at 24 h post-treatment (data not shown), all treatments, except the one with sorafenib 
alone, significantly decreased the migration of spheroids at 48 and 72 h (Fig. 9).  
 
3.5. Cambinol and EX-527 affect the expression of some ABC transporters during sorafenib treatment  
We explored the effect of adding cambinol or EX-527 to sorafenib treatment on the expression of P-gp, MRP3, 
BCRP and MRP2 in 2D cultures from HepG2 and Huh7 cells. As shown in Fig. 10, cambinol alone decreased 
the expression of P-gp and MRP3 in HepG2 cells but augmented the expression of all the studied transporters in 
Huh7 cells. P-gp expression decreased in HepG2 cells but augmented in Huh7 cells in response to EX-527. The 
expression of MRP3 and BCRP was reduced and a trendo decrease in MRP2 expression was found after the 
treatment with EX-527 in both HCC cell lines. Additionally, sorafenib induced an increase in MRP3 exprssion 
and a trend to increase the expression of some of the other transporters, in both cell lines. In HepG2 cells, 
combined treatments diminished the expression of P-gp and MRP3 with respect to sorafenib treatment and, in 
the case of P-gp, the levels found were even lower than those of the control group. Also, the expression of BCRP 
decreased with the presence of EX-527 in the combined treatment in this cell line. In the Huh7 cell line, the 
presence of cambinol in the combined treatment raised the expression of all the studied transporters. Finally, in 
Huh7 cells, the presence of EX-527 in the combined tr atment augmented the expression of P-gp but was able to 
reduce the level of MRP3 and BCRP compared with sorafenib treatment. 
 
4. Discussion 
There is an urgent need to improve HCC sensitivity to sorafenib. The aim of this study was to analyze the impact 











The IC50 values found for sorafenib in the cytotoxic studies were similar to those reported in the literature and 
were within the clinically relevant concentration range for this drug (K. F. Chen et al., 2011; Cui et al., 2014; 
Jiang et al., 2015; Khawar et al., 2018; Lin et al., 2020; Liu et al., 2006). SIRTs inhibitors exacerbated the effects 
of sorafenib on the viability of 2D and 3D cultures of HepG2 and Huh7 cells. To our knowledge, there are no 
studies showing the effects of combination of sorafenib with cambinol, EX-527 or other SIRTs 1 and 2 
inhibitors, although it is worth mentioning that Chen et al. (Chen et al., 2012) demonstrated that SIRT1 
overexpression promoted resistance to sorafenib in the HCC cell line SK-Hep1.  
It was reported that cambinol and EX-527 (Holloway et al., 2010; Kang et al., 2018; Ponnusamy et al., 2014) as 
well as the knockdown of SIRT1 and SIRT2 (Ponnusamy et al., 2014; Pruitt et al., 2006) reduced the expr ssion 
of PCNA and cyclin D1 in diverse cell lines. In addition, Chen et al. (Chen et al., 2019) showed that Ki-67 
protein level greatly decreased in SIRT1 knockdown and EX-527-treated glioma tumors established in nude 
mice. Regarding SIRT2, one work demonstrated that Ki-67 expression was increased after SIRT2 
overexpression in a myoblast cell line (Wu et al., 2014). Specifically in HCC cells, it was only described the 
reduction of PCNA and cyclin D1 expression after SIRT1 silencing (Bae et al., 2014); and SIRT1 expression 
was positively correlated with Ki-67 expression in human HCC tissues (Jang et al., 2012). In our study, 
combined treatments were effective in decreasing the proliferation of 2D cultures and 3D cultures treaed with 
sorafenib in the presence of SIRTs inhibitors showed a greater fall in spheroid growth. In addition, the strongest 
reduction in proliferative cells was observed in sections obtained from HepG2 spheroids treated with sorafenib in 
the presence of SIRTs inhibitors, consistent with the smallest volumes of spheroids and the largest decrease in 
cellular proliferation found under this condition. I  Huh7 spheroids, the presence of cambinol in the combined 
treatment was capable of diminishing the number of Ki-67- and PCNA-positive cells when compared to 
sorafenib treatment. To our knowledge, this is the first work aimed to explore the effect of sorafenib or SIRTs 
inhibitors on these proliferation markers in 3D cultures.  
The gradient of proliferation characteristic of 3D cultures (Mehta et al., 2012) was clearly visible in sections of 
spheroids from both cell lines immunostained for Ki-67, PCNA and cyclin D1. This pattern of staining was 
already described for Ki-67 and PCNA in sections obtained from spheroids of HCC cell lines (Baulies et al., 
2018; Jung et al., 2017). This is the first work describing the expression of cyclin D1 in 3D cell cultures from 
HCC cells. Laurent et al. (Laurent et al., 2013) showed that spheroids from pancreatic cancer cells displayed an 










It is interesting to note that Ki-67, PCNA and cyclin D1 are prognostic biomarkers related to tumor grwth rate 
and poor prognosis in HCC (Burkhart et al., 2017). In this regard, the fact that combined treatments decreased 
the expression of these proliferation markers in 3D cell cultures could be of extreme value in identifying 
clinically relevant therapies with a higher predictive value for clinical outcome (Langhans, 2018).  
It was described that cambinol lead to a G0/G1 arrest in HepG2 cells (Portmann et al., 2013) and that EX-527 
also caused cell cycle arrest at G0/G1 in other cancer cell lines (Peck et al., 2010; Singh et al., 2015). In our 
work, combined treatments presented more growth arrest in G1/G0 phase of cell cycle regarding sorafenib alone.  
In the current study, we were able to detect caspase-3/7 staining in the core region of whole control spheroids 
consistent with apoptosis induction within the nutrient deprived spheroid core (Mehta et al., 2012). Interestingly, 
2D and 3D cultures treated with sorafenib in the presence of SIRTs 1 and 2 inhibitors exhibited more apoptosis 
than cultures treated only with sorafenib. Although there are no studies evaluating the impact of SIRTs 1 and 2 
inhibitors on sorafenib apoptosis, Garten et al. (Garten et al., 2019) proposed recently that SIRT1 overexpression 
could be an underlying mechanism of sorafenib resistance in HCC since transient overexpression of SIRT1 
decreased sorafenib-induced apoptosis in Huh7 cells.  
It was reported that SIRTs 1 and 2 knockdowns significantly reduced migration and invasion in HCC cell lines 
and HCC tumor metastasis in vivo (Chen et al., 2013; Hao et al., 2014; Li et al., 2016). In our study, the addition 
of SIRTs 1 and 2 inhibitors potentiated the effect of sorafenib to inhibit cellular migration and invasion. 
Sorafenib induced the expression of MRP3 in 2D cultures of both HCC cell lines. Even though HCC cell lines 
resistant to sorafenib have more MRP3 expression tha  t e corresponding parental cells (Chow et al., 2013; 
Tomonari et al., 2016), the effect of sorafenib on MRP3 expression in sensitive HCC cells has not been studied.  
Combined treatments showed less expression of P-gp and MRP3 than the individual treatment with sorafenib i  
HepG2 cells. In addition, the expression of BCRP decreased with the addition of EX-527 to the combined 
treatment in this cell line. In accordance with ourprevious study (Ceballos et al., 2018), cambinol ad EX-527 
reduced P-gp and MRP3 expression in HepG2 cells. In these cells, we also found that EX-527 was able to r duce 
BCRP protein levels. In line with our results, the inhibitory effect of EX-527 on P-gp expression was already 
reported in non-HCC cancer cell lines (H.-B. Kim et al., 2015; Zhu et al., 2012) and Wen et al. (Wen et al., 
2020) showed recently that EX-527 inhibited the expr ssion of MRP3 and raised 5‑Fluorouracil sensitivity in 
5‑Fluorouracil-resistant HCC tumors established in nude mice. Additionally, BCRP expression was remarkably 
inhibited by transfection of non-HCC cancer cell lines with SIRT1 siRNAs (H. B. Kim et al., 2015; Wang et al., 










breast cancer cells (Choi et al., 2013), we only found a trend to decrease in MRP2 expression in EX-527-treated 
cells. In contrast to HepG2 cells, treatment with cambinol, alone or in combination with sorafenib, induced the 
expression of all the studied transporters in Huh7 cells. Even though EX-527 increased the expression of P-gp, 
this drug was able to diminish the expression of MRP3 and BCRP in Huh7 cells. In accordance with this,e 
addition of EX-527 to the combined treatment augmented the expression of P-gp and reduced the expression of 
MRP3 and BCRP compared with sorafenib treatment in these cells. Although we do not know the mechanism 
involved in the dissimilar behavior between HCC cell lines, we believe that the p53 suppressor protein could 
play a key role. HepG2 cells express a wild-type form f p53 whereas Huh7 cells express a mutant form of this 
protein (Hsieh et al., 2003). It was observed that whereas wild-type p53 generally represses MDR1 promoter, 
some mutants of p53 stimulate its activity (Zastawny et al., 1993). In fact, certain p53 mutants upregulated P-gp 
expression and activity in cancer cells, including i  a HCC cell line (Chan and Lung, 2004; Tsou et al., 2015). 
This mechanism could be also responsible for the dissimilar behavior between P-gp and MRP3 and BCRP in 
Huh7 cells when only considering the specific SIRTs 1 and 2 inhibitor EX-527, since it was described that 
cambinol lacks selectivity and targets more than SIRT1 and SIRT2 (Lugrin et al., 2013) and thus could be 
activating alternative pathways to modulate the expr ssion of ABC transporters. Moreover, despite studies are 
still needed regarding MRP3, it was reported in vitro and in vivo that sorafenib is moderately transported by P-
gp, being a weak substrate of this ABC transporter, and more efficiently by BCRP (Gnoth et al., 2010; Lagas et 
al., 2010). In this way, Gnoth and col. (Gnoth et al., 2010) conclude that it is unlikely that P-gp has a major 
effect on the plasma concentrations of sorafenib in humans. On the other hand, in HCC cell lines, it was showed 
that BCRP mediated the efflux of sorafenib (Huang et al., 2013) and that MRP3 and BCRP are involved in 
sorafenib resistance (Huang et al., 2013; Tomonari et al., 2016; Wang et al., 2020). In spite that resistance 
mechanisms underlying the impaired sensitivity to sorafenib are still elusive and the role of ABC transporters in 
this resistance remains to be better elucidated (Beretta et al., 2017), it is probably that BCRP and MRP3 are 
being part of the mechanism that takes place during SIRTs 1 and 2 inhibition to enhance the response of HCC 
cells to sorafenib. Studies with SIRTs 1 and 2 inhibitors are still missing in sorafenib-resistant cells to better 
elucidate the role of ABC transporters in sorafenib resistance. Conversely, uncontrolled cell proliferation due to 
defects throughout cell cycle progression and apoptosis resistance are widely accepted characteristic of umor 
cells and reported mechanisms of sorafenib therapy failure (Niu et al., 2017). Thus, mechanisms related to the 









implicated in enhancing the response of HCC cells to sorafenib as well. Additionally, modulation of p53 and 
FoxO1 acetylation levels by cambinol and EX-527 treatments (Ceballos et al., 2018) could also be involved.  
Finally, it is worthy to highlight our results in 3D cultures, as spheroids are considered good predictors of the 
therapeutic response in patients (Langhans, 2018). In fact, many treatments are expected to lose efficacy when 
tested in 3D cultures (Hirschhaeuser et al., 2010). Thus, a potentially relevant observation in our stdy was that 
the beneficial effects of adding cambinol or EX-527 to sorafenib-treated cells were maintained when moving 
from 2D to 3D cultures, suggesting that the inhibition of SIRTs 1 and 2 could be effective in sensitizing HCC 
cells to sorafenib treatment in vivo. In this connection, cambinol and EX-527 were already tested in vivo, being 
effective in inhibiting tumor growth in murine models of cancer and, at the same time, well tolerated by mice 
without induction of weight loss or adverse effects (A aka et al., 2015; Chen et al., 2017; Heltweg et al., 2006; 
Marshall et al., 2011; Portmann et al., 2013). In fact, cambinol impaired HCC growth in an orthotopic xenograft 
model and displayed no signs of hepatic damage or impairment of the regenerative capacity of normal liver in 
response to partial hepatectomy (Portmann et al., 2013). Furthermore, EX-527 was tested in phase I and II 
clinical trials for the treatment of Huntington’s disease (a neurodegenerative disorder) and was found t  be safe 
and well tolerated by patients (Süssmuth et al., 2015) and by healthy volunteers as well (Westerberg et al., 2015). 
Although more research is still necessary in order to evaluate the safety of combining SIRTs inhibitors with 
chemotherapeutic agents, findings presented in this manuscript shed some light on the importance of this type of 
research at the preclinical as well as the clinical levels. 
 
5. Conclusions  
This manuscript described that cambinol and EX-527 enhanced the response of HCC cells to 
sorafenib treatment. As PCNA, cyclin D1 and Ki-67 are closely associated with cell proliferation and caspase-
3/7 orchestrate apoptosis, their modulation in the presence of SIRTs 1 and 2 inhibitors likely play an important 
role in enhancing the response of HCC cells to sorafenib treatment. The presence of EX-527, a specific SIRTs 1 
and 2 inhibitor, was able to reduce MRP3 and BCRP expression in sorafenib-treated HCC cells, suggesting that 
modulation of ABC transporters may be involved, at le st in part, in the beneficial effects of combined 
treatments. Treatments were still effective in 3D cultures yielding results with higher predictive value for clinical 
outcome and thus providing a rationale for clinically exploring the use of SIRTs 1 and 2 inhibitors in HCC 
therapy to sensitize cells to sorafenib. At the same ti e, since the addition of SIRTs 1 and 2 inhibitors to 










will impact in the reduction of appearance of adverse effects and in the quality of life of patients with HCC 
under therapy.  
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Fig. 1. Effect of SIRTs inhibitors on cellular viability and colony formation upon sorafenib treatment 
conditions in 2D cultures. A) MTT assay: HCC cells were incubated for 72 h with different doses of sorafenib 
to obtain the dose-response curves. B) MTT assay: HepG2 and Huh7 cells were incubated for 72 h with 2 μM or 
1 μM sorafenib (Sfb 2 or Sfb 1), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 
40 μM EX-527 (Sfb + EX 40). Also, HCC cells were treated with 50 μM cambinol (Camb 50) or 40 μM EX-527 
(EX 40) in the absence of sorafenib. A, B) Cell viability is expressed in percent value with control cells 
arbitrarily considered 100%. At least 3 independent experiments; n=3 in each one. C) Clonogenic assay: HepG2 
and Huh7 cells were treated as in B) and then were grown in fresh culture media for 7 days. Representative wells 
are shown for both HCC cell lines. Data are expressed as a percentage of colonies in control cells (arbitr ily 
considered 100%) of three independent experiments, ach of which was performed in duplicate. Mean ± S.E.M; 
*P < 0.05 vs. control; #P < 0.05 vs. Sfb; $P < 0.05 vs. Camb 50; &P < 0.05 vs. EX 40.  
 
Fig. 2. Effect of cambinol and EX-527 on spheroid viability during sorafenib treatment. APH assay: A) 3D 
cultures of HCC cells were incubated for 72 h with different doses of sorafenib to obtain the dose-respon e 
curves. B) 3D cultures of HepG2 and Huh7 cells were incubated for 72 h with 4 μM or 2 μM sorafenib (Sfb 4 or 
Sfb 2), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 80 μM or 40 μM EX-527 
(Sfb + EX 80 or Sfb + EX 40), respectively. Also, 3D cultures were treated with 50 μM cambinol (Camb 50) or 
80 μM EX-527 (EX 80) for HepG2 and 40 μM EX-527 (EX 40) for Huh7 in the absence of sorafenib. A, B) Cell 
viability is expressed in percent value with control spheroids arbitrarily considered 100%. At least 3 independent 
experiments; n=8 in each one. Mean ± S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb; $P < 0.05 vs. Camb 50; 
&P < 0.05 vs. EX.  
 
Fig. 3. Effect of SIRTs inhibitors on proliferation upon sorafenib treatment conditions in 2D cultures. 
HepG2 and Huh7 cells were incubated for 72 h with 2 μM or 1 μM sorafenib (Sfb 2 or Sfb 1), respectively, alone 
or in combination with 50 μM cambinol (Sfb + Camb 50) or 40 μM EX-527 (Sfb + EX 40). Also, HCC cells 
were treated with 50 μM cambinol (Camb 50) or 40 μM EX-527 (EX 40) in the absence of sorafenib. A, B) 










were cropped from different parts of the same gel and they are shown after cropping, aligning and separating 
them by a white space. Densitometric analysis was performed and results are expressed in percent values with 
control cells arbitrarily considered 100%. Three independent experiments; n = 3 in each one. C) Cell cycle 
analysis: Cells were fixed, stained with propidium iodide, and their distribution in cell cycle was analyzed by 
flow cytometry. Bar charts show the percentage of cells in G0/G1 and S phases of the cell cycle. Two 
independent experiments; n = 3 in each one. Mean ± S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb; $P < 0.05 
vs. Camb 50; &P < 0.05 vs. EX 40.  
 
Fig. 4. Effect of cambinol and EX-527 on spheroid growth during sorafenib treatment. Spheroid growth 
delay assay: A) 3D cultures of HCC cells were incubated for 72 h with different doses of sorafenib to obtain the 
dose-response curves. B, C) 3D cultures of HepG2 and Huh7 cells were incubated for 72 h with 4 μM or 2 μM 
sorafenib (Sfb 4 or Sfb 2), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 80 
μM or 40 μM EX-527 (Sfb + EX 80 or Sfb + EX 40), respectively. Also, 3D cultures were treated with 50 μM 
cambinol (Camb 50) or 80 μM EX-527 (EX 80) for HepG2 and 40 μM EX-527 (EX 40) for Huh7 in the absence 
of sorafenib. B) Representative images of spheroids before (0 h) and after 72 h of treatment are shown for both 
HCC cell lines. Scale bar 200 µm. A, C) Results are expressed as the percentage of volume at 72 h vs. 0 h with 
control spheroids arbitrarily considered 100%. At least 3 independent experiments; n=8 in each one. Mean ± 
S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb; $P < 0.05 vs. Camb 50; &P < 0.05 vs. EX.  
 
Fig. 5. Effect of SIRTs inhibitors on spheroid proliferation upon sorafenib treatment conditions. 
Immunofluorescence: 3D cultures of HepG2 and Huh7 cells were incubated for 72 h with 4 μM or 2 μM 
sorafenib (Sfb 4 or Sfb 2), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 80 
μM or 40 μM EX-527 (Sfb + EX 80 or Sfb + EX 40), respectively. Also, 3D cultures were treated with 50 μM 
cambinol (Camb 50) or 80 μM EX-527 (EX 80) for HepG2 and 40 μM EX-527 (EX 40) for Huh7 in the absence 
of sorafenib. Representative images of spheroids sections of A) HepG2 and B) Huh7 cells visualized by confocal 
microscopy showing the expression of Ki-67 in green and PCNA and cyclin D1 in red. Nuclei were stained with 
DAPI (blue). Scale bar 200 µm. The fraction of the proliferation marker-positive cells (proliferation 
marker/DAPI) and the total number of the proliferation marker-positive cells per section of spheroid is shown for 










considered 100%. Two independent experiments; n=8. Mean ± S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb; 
$P < 0.05 vs. Camb; &P < 0.05 vs. EX. 
 
Fig. 6. Effect of cambinol and EX-527 on apoptosis upon sorafenib treatment conditions in 2D cultures. 
HepG2 and Huh7 cells were incubated for 72 h with 2 μM or 1 μM sorafenib (Sfb 2 or Sfb 1), respectively, alone 
or in combination with 50 μM cambinol (Sfb + Camb 50) or 40 μM EX-527 (Sfb + EX 40). Also, HCC cells 
were treated with 50 μM cambinol (Camb 50) or 40 μM EX-527 (EX 40) in the absence of sorafenib. A) 
Annexin V/propidium iodide assay: Early (EA) and late (LA) apoptosis is expressed in percent value with
control cells arbitrarily considered 100%. Three independent experiments, each of which was performed in 
duplicate. Mean ± S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb; $P < 0.05 vs. Camb 50; &P < 0.05 vs. EX 40. 
B) Caspase-3/7 activation assay: Representative images are shown for cells stained with CellEvent™ Caspase-
3/7 Green ReadyProbes™ Reagent for 30 min and observed under fluorescent microscope. Green fluorescence 
corresponds to caspase-3/7-positive cells.  
 
Fig. 7. Effect of SIRTs inhibitors on spheroid apoptosis during sorafenib treatment. Caspase-3/7 activation 
assay: 3D cultures of HepG2 and Huh7 cells were incubated for 72 h with 4 μM or 2 μM sorafenib (Sfb 4 or Sfb 
2), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 80 μM or 40 μM EX-527 
(Sfb + EX 80 or Sfb + EX 40), respectively. Also, 3D cultures were treated with 50 μM cambinol (Camb 50) or 
80 μM EX-527 (EX 80) for HepG2 and 40 μM EX-527 (EX 40) for Huh7 in the absence of sorafenib. A) 
Representative images are shown for spheroids stained with CellEvent™ Caspase-3/7 Green ReadyProbes™ 
Reagent for 1 h and observed under fluorescent microscope. Green fluorescence corresponds to caspase-3/7 
activation. The white dotted line corresponds to the edge of the spheroid. Scale bar 200 µm. B) Data are 
expressed as the percentage of apoptosis in control spheroids (arbitrarily considered 100%). Three independent 
experiments; n = 2 in each one. Mean ± S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb; $P < 0.05 vs. Camb 50; 
&P < 0.05 vs. EX.  
 
Fig. 8. Effect of cambinol and EX-527 on migration and invasion during sorafenib treatment in 2D 
cultures. A, B) Wound healing assay: HepG2 and Huh7 cells were treated with 2 μM or 1 μM sorafenib (Sfb 2 
or Sfb 1), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 40 μM EX-527 (Sfb + 










absence of sorafenib. A) Representative wound images are shown before and after 24 h of treatment. B) The 
distance migrated by cells is expressed in percent value with control cells arbitrarily considered 100%. C) 
Transwell cell invasion assay: Huh7 cells were treated as above. Representative images of cells that inv ded the 
lower chamber after 48 h of treatment are shown. Cellular invasion is expressed in percent value with control 
cells arbitrarily considered 100%. A-C) Three independent experiments; 18 fields/well and 15 fields/well for 
wound healing and transwell cell invasion assays, respectively, in each experiment. Mean ± S.E.M; *P < 0.05 vs. 
control; #P < 0.05 vs. Sfb; $P < 0.05 vs. Camb 50; &P < 0.05 vs. EX 40.  
 
Fig. 9. Effect of SIRTs inhibitors on spheroid migration upon sorafenib treatment conditions. Spheroid 
migration assay: 3D cultures of Huh7 cells were incubated for 48 h and 72 h with 2 μM sorafenib (Sfb 2), alone 
or in combination with 50 μM cambinol (Sfb + Camb 50) or 40 μM EX-527 (Sfb + EX 40). Also, 3D cultures of 
Huh7 cells were treated with 50 μM cambinol (Camb 50) or 40 μM EX-527 (EX 40) in the absence of sorafenib. 
A) Representative images of migrating spheroids before (0 h) and after 48 h and 72 h of treatment. The black 
dotted line corresponds to the migration front. Scale b r 200 µm. B) Data are expressed as the percentage of 
migrated area in control spheroids (arbitrarily considered 100%). Three independent experiments; n = 8 in each 
one. Mean ± S.E.M; *P < 0.05 vs. control; #P < 0.05 vs. Sfb 2; $P < 0.05 vs. Camb 50.  
 
Fig. 10. Effect of cambinol and EX-527 on ABC transporters expression during sorafenib treatment in 2D 
cultures. Western blot: HepG2 and Huh7 cells were incubated for 72 h with 2 μM or 1 μM sorafenib (Sfb 2 or 
Sfb 1), respectively, alone or in combination with 50 μM cambinol (Sfb + Camb 50) or 40 μM EX-527 (Sfb + 
EX 40). Also, HCC cells were treated with 50 μM cambinol (Camb 50) or 40 μM EX-527 (EX 40) in the 
absence of sorafenib. A) P-gp, B) MRP3, C) BCRP and D) MRP2 protein levels. β-actin was probed as loading 
control. Selected lanes were cropped from different par s of the same gel and they are shown after cropping, 
aligning and separating them by a white space. Densitometric analysis was performed and results are expressed 
in percent values with control cells arbitrarily considered 100%. Three independent experiments; n = 3in each 
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